US · TWST
Twist Bioscience Corporation
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- South San Francisco, CA 94080
- Website
- twistbioscience.com
Price · as of 2025-09-30
$60.40
Market cap 2.88B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.38 | -41.42% |
| Intrinsic Value(DCF) | $16.00 | -73.51% |
| Graham-Dodd Method(GD) | $0.04 | -99.93% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $28.55 | $44.53 | $165,634.09 | $0.00 | $0.00 |
| 2019 | $24.74 | $34.58 | $303,361.05 | $0.00 | $0.00 |
| 2020 | $141.65 | $74.56 | $4,950.77 | $0.00 | $0.00 |
| 2021 | $83.10 | $57.11 | $186.80 | $0.00 | $0.00 |
| 2022 | $24.42 | $27.67 | $9.84 | $0.00 | $0.00 |
| 2023 | $26.98 | $25.64 | $4.14 | $0.00 | $0.00 |
| 2024 | $52.70 | $41.80 | $18.17 | $0.00 | $0.00 |
| 2025 | $32.30 | $35.38 | $13.08 | $0.04 | $0.00 |
AI valuation
Our deep-learning model estimates Twist Bioscience Corporation's (TWST) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.38
- Current price
- $60.40
- AI upside
- -41.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$16.00
-73.51% upside
Graham-Dodd
$0.04
-99.93% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TWST | Twist Bioscience Corporat… | $60.40 | 2.88B | -41% | -74% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
| BGM | BGM Group Ltd. | $1.11 | 222.69M | +3,719% | +391% | +343% | +545% | -40.44 | 1.44 | 2.44 | 49.11 | — | 1.61 | 16.39% | -2.25% | -5.75% | -3.55% | -1.76% | -2.91% | 0.00 | -0.88 | 3.39 | 2.73 | -11.16 | -8148.00% | -4599.00% | -43.00% | -5.52% | 0.06 | -14.87% | 0.00% | 0.00% | 4.76% | -76.65 | -12.76 | 1.72 | 5.16 |
| CLOV | Clover Health Investments… | $2.09 | 1.08B | +1,430% | +6,971% | — | — | -12.33 | 3.42 | 0.55 | -11.45 | -13.17 | 3.45 | 103.58% | -4.44% | -4.45% | -26.33% | -51.38% | -15.25% | 0.00 | — | 1.47 | 0.46 | 0.93 | 9362.00% | 4034.00% | -30721.00% | -6.54% | -0.32 | -41.43% | 0.00% | 0.00% | 0.10% | -11.22 | -13.92 | 0.50 | 0.06 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| GRDN | Guardian Pharmacy Service… | $33.51 | 2.12B | -11% | +240% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| PRCT | PROCEPT BioRobotics Corpo… | $22.69 | 1.27B | +83% | +106% | — | — | -15.10 | 3.94 | 4.69 | -15.09 | — | 3.95 | 63.70% | -33.71% | -31.02% | -24.89% | -74.26% | -18.34% | 0.14 | -11.69 | 6.85 | 5.62 | 2.93 | -171.00% | 3722.00% | -4370.00% | -4.04% | -0.74 | -41.71% | 0.00% | 0.00% | 0.44% | -11.64 | -20.71 | 3.92 | 5.16 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
- CEO
- Emily Marine Leproust
- Employees
- 923
- Beta
- 2.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($16.00 ÷ $60.40) − 1 = -73.51% (DCF, example).